Education
About Us
Working with TipRanks
Follow Us
Adam Rogers Insider Profile
4 Followers
Adam Rogers, Chairman & Interim Chief Executive Officer, Ten Percent Owner at NervGen Pharma, holds 14.71M shares in NervGen Pharma (Ticker: NGENF). Most recently, Adam Rogers Bought 1,809,524 shares of NervGen Pharma on Nov 20, 2025 for an estimated value of $3.80M.
Adam Rogers NervGen Pharma (NGENF)Chairman & Interim Chief Executive Officer, Ten Percent Owner
NervGen Pharma (NGENF)
Chairman & Interim Chief Executive Officer, Ten Percent Owner
Not Ranked
Adam Rogers has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Chairman & Interim Chief Executive Officer, Ten Percent Owner
Roles that Adam Rogers holds in companies
Most Profitable Insider Trade
The most profitable trade made by Adam Rogers
Adam Rogers's Trading History
List of latest transactions for each holding click on a transaction to see Adam Rogers's performance on stock
You May Also Like
Adam Rogers insider profile FAQ
What is the percentage of profitable transactions made by Adam Rogers?
The percentage of profitable transactions made by Adam Rogers is ―.
What is the average return per transaction made by Adam Rogers?
The average return per transaction made by Adam Rogers is ―.
What stocks does Adam Rogers hold?
Adam Rogers holds: NGENF stocks.
What was Adam Rogers’s latest transaction?
Adam Rogers latest transaction was an Informative Buy of $3.80M.
What was Adam Rogers's most profitable transaction?
Adam Rogers’s most profitable transaction was an Informative Buy of NGENF stock on November 20, 2025. The return on the trade was 80.80%.
What is Adam Rogers's role in NervGen Pharma?
Adam Rogers's role in NervGen Pharma is Chairman & Interim Chief Executive Officer, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.